PMID- 33106846 OWN - NLM STAT- MEDLINE DCOM- 20210628 LR - 20210628 IS - 1462-0332 (Electronic) IS - 1462-0324 (Print) IS - 1462-0324 (Linking) VI - 60 IP - 4 DP - 2021 Apr 6 TI - Elevated serum level of hepatocyte growth factor predicts development of new syndesmophytes in men with ankylosing spondylitis. PG - 1804-1813 LID - 10.1093/rheumatology/keaa460 [doi] AB - OBJECTIVES: To study baseline serum hepatocyte growth factor (s-HGF) as a predictor of spinal radiographic progression overall and by sex and to analyse factors correlated to changes in s-HGF in patients with AS. METHODS: At baseline and the 5-year follow-up, s-HGF was analysed with ELISA. Spinal radiographs were graded according to modified Stoke Ankylosing Spondylitis Spinal Score. Radiographic progression was defined as >/=2 modified Stoke Ankylosing Spondylitis Spinal Score units/5 years or development of >/=1 syndesmophyte. Logistic regression analyses were used. RESULTS: Of 204 baseline participants, 163 (80%) completed all examinations at the 5-year follow-up (54% men). Baseline s-HGF was significantly higher in men who developed >/=1 syndesmophyte compared with non-progressors, median (interquartile range) baseline s-HGF 1551 (1449-1898) vs 1436 (1200-1569) pg/ml, P = 0.003. The calculated optimal cut-off point for baseline s-HGF >/=1520 pg/ml showed a sensitivity of 70%, a specificity of 69% and univariate odds radio (95% CI) of 5.25 (1.69, 14.10) as predictor of development of >/=1 new syndesmophyte in men. Baseline s-HGF >/=1520 pg/ml remained significantly associated with development of >/=1 new syndesmophyte in men in an analysis adjusted for the baseline variables age, smoking, presence of syndesmophytes and CRP, odds radio 3.97 (1.36, 11.60). In women, no association with HGF and radiographic progression was found. Changes in s-HGF were positively correlated with changes in ESR and CRP. CONCLUSION: In this prospective cohort study elevated s-HGF was shown to be associated with development of new syndesmophytes in men with AS. CI - (c) The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. FAU - Deminger, Anna AU - Deminger A AD - Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Region Vastra Gotaland, Sahlgrenska University Hospital, Department of Rheumatology, Gothenburg, Sweden. FAU - Klingberg, Eva AU - Klingberg E AD - Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Region Vastra Gotaland, Sahlgrenska University Hospital, Department of Rheumatology, Gothenburg, Sweden. FAU - Nurkkala, Merja AU - Nurkkala M AD - Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Geijer, Mats AU - Geijer M AD - Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Region Vastra Gotaland, Sahlgrenska University Hospital, Department of Radiology, Gothenburg, Sweden. AD - Department of Clinical Sciences, Lund University, Lund, Sweden. FAU - Carlsten, Hans AU - Carlsten H AD - Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Region Vastra Gotaland, Sahlgrenska University Hospital, Department of Rheumatology, Gothenburg, Sweden. FAU - Jacobsson, Lennart T H AU - Jacobsson LTH AD - Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. FAU - Forsblad-d'Elia, Helena AU - Forsblad-d'Elia H AD - Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. AD - Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Rheumatology (Oxford) JT - Rheumatology (Oxford, England) JID - 100883501 RN - 0 (Biomarkers) RN - 67256-21-7 (Hepatocyte Growth Factor) RN - 9007-41-4 (C-Reactive Protein) SB - IM MH - Adult MH - Biomarkers/blood MH - Blood Sedimentation MH - C-Reactive Protein/analysis MH - Cervical Vertebrae/diagnostic imaging MH - Cohort Studies MH - *Disease Progression MH - Female MH - Follow-Up Studies MH - Hepatocyte Growth Factor/*blood MH - Humans MH - Lumbar Vertebrae/diagnostic imaging MH - Male MH - Middle Aged MH - Radiography MH - Spondylitis, Ankylosing/*diagnostic imaging PMC - PMC8023989 OTO - NOTNLM OT - AS OT - hepatocyte growth factor OT - outcomes research EDAT- 2020/10/28 06:00 MHDA- 2021/06/29 06:00 PMCR- 2020/10/27 CRDT- 2020/10/27 05:47 PHST- 2020/04/01 00:00 [received] PHST- 2020/07/03 00:00 [revised] PHST- 2020/10/28 06:00 [pubmed] PHST- 2021/06/29 06:00 [medline] PHST- 2020/10/27 05:47 [entrez] PHST- 2020/10/27 00:00 [pmc-release] AID - 5940679 [pii] AID - keaa460 [pii] AID - 10.1093/rheumatology/keaa460 [doi] PST - ppublish SO - Rheumatology (Oxford). 2021 Apr 6;60(4):1804-1813. doi: 10.1093/rheumatology/keaa460.